GlassScriptPhysician profile
Michelle Angus
NPI 1336651504
$2,259.12
in general payments reported to CMS, 2019-2025
11 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $412 · 2023: $396 · 2024: $578 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $605.55 | 2021-2025 | Ingrezza |
| Novo Nordisk INC | $377.65 | 2021-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $336.79 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.81 | 2022-2023 | |
| Silk Road Medical, INC. | $147.70 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Abbott Laboratories | $126.76 | 2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $120.98 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $116.49 | 2022-2023 | Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $104.41 | 2023 | Farxiga |
| Abbvie INC. | $97.00 | 2022 | |
| Alkermes, INC. | $13.98 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Angus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.